Cost of hemophilia A in Turkey: an economic disease burden analysis

Malhan S., Oksuz E., Antmen B., Ar M. C., BALKAN C., Kavakli K.

JOURNAL OF MEDICAL ECONOMICS, vol.24, no.1, pp.1052-1059, 2021 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 24 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1080/13696998.2021.1965388
  • Journal Name: JOURNAL OF MEDICAL ECONOMICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Page Numbers: pp.1052-1059
  • Keywords: Hemophilia A, costs and cost analysis, drug costs, blood coagulation factors, QUALITY-OF-LIFE, CARE, MANAGEMENT, INHIBITORS, IMPACT
  • Istanbul University Affiliated: Yes

Abstract

Objective: Hemophilia A is the second most common bleeding disorder causing patients to have lifelong follow-up and treatment. Despite being a rare disease, hemophilia A has a high economic burden on individuals and the public. The purpose of this study was to estimate the total disease cost of hemophilia A in Turkey.